GlassScriptPhysician profile
Gargi Patel
NPI 1740727411
$12,445.18
in general payments reported to CMS, 2019-2025
31 companies · $9,414 in 2025
The $9,414 reported for 2025 was more than what 88% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.78 · 2020: $179 · 2021: $687 · 2022: $707 · 2023: $102 · 2024: $1,308 · 2025: $9,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,400 · Food and Beverage: $3,633 · Consulting Fee: $1,719 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,400.00 |
| Food and Beverage | $3,633.07 |
| Consulting Fee | $1,719.00 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $5,581.97 | 2025 | Dawnzera |
| Genzyme Corporation | $3,351.30 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $602.43 | 2019-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $462.41 | 2020-2025 | Nucala |
| Genentech USA, INC. | $393.77 | 2024-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $234.77 | 2019-2025 | |
| Csl Behring | $179.03 | 2020-2025 | Haegarda, Andembry |
| Ars Pharmaceuticals Operations, INC. | $178.91 | 2025 | Neffy |
| Pharming Healthcare, INC. | $170.70 | 2024-2025 | Ruconest |
| Organon LLC | $150.29 | 2025 | Vtama |
| Takeda Pharmaceuticals U.S.A., INC. | $147.68 | 2020-2025 | Cuvitru |
| Biocryst US Sales Co., LLC | $144.73 | 2021-2025 | Orladeyo |
| Incyte Corporation | $142.62 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $111.36 | 2021-2022 | |
| Pfizer INC. | $87.47 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $77.55 | 2024-2025 | Sajazir |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $68.23 | 2021-2023 | Airduo Digihaler |
| Lilly USA, LLC | $49.05 | 2024-2025 | Ebglyss |
| Abbvie INC. | $39.18 | 2022-2023 | |
| Amgen INC. | $33.01 | 2025 | Tezspire |
| Galderma Laboratories, L.P. | $31.25 | 2025 | Nemluvio |
| Hikma Pharmaceuticals USA | $23.88 | 2025 | Ryaltris |
| Kaleo, INC. | $16.58 | 2024 | Auvi-Q |
| Phadia US INC. | $15.46 | 2024 | Immunocap |
| Mallinckrodt Hospital Products INC. | $15.28 | 2025 | Acthar |
| Alk-Abello, INC | $14.87 | 2019 | |
| Horizon Therapeutics Plc | $12.85 | 2020 | |
| Aimmune Therapeutics, INC. | $12.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.94 | 2022 | |
| Grifols USA, LLC | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gargi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.